Aetna Updates Coverage Policy for Calcitriol, Etelcalcetide, and Paricalcitol Injections (CPB 0022)

Aetna has issued a modification to Clinical Policy Bulletin 0022, covering injectable vitamin D analogs and calcimimetics used primarily in chronic kidney disease (CKD) and end-stage renal disease (ESRD) management. The effective date for this updated policy is February 13, 2026. If your practice or facility bills for calcitriol, etelcalcetide, or paricalcitol injections in a nephrology, dialysis, or hospital outpatient setting, this policy deserves your immediate attention.

What Aetna's CPB 0022 Covers: Calcitriol, Etelcalcetide, and Paricalcitol Injections

Aetna, a CVS Health company, maintains Clinical Policy Bulletin 0022 as its governing document for injectable forms of calcitriol (the active form of vitamin D), paricalcitol (a synthetic vitamin D analog), and etelcalcetide (a calcimimetic agent marketed as Parsabiv). These medications are used to manage secondary hyperparathyroidism (SHPT) in patients with CKD on dialysis—a population where precise coverage criteria and billing accuracy directly affect both patient care and revenue integrity.

All three agents work through different mechanisms to control parathyroid hormone (PTH) levels, calcium, and phosphorus in ESRD patients. Because they represent significant drug spend, especially in the dialysis setting, Aetna's coverage criteria for each tends to be specific and condition-dependent. The February 2026 modification signals at minimum a review and update of those criteria, which means assumptions from prior authorization approvals under older versions of this policy may no longer hold.

The full source document is available directly via Aetna's CPB 0022 on PayerPolicy.

Clinical Context: Why This Policy Matters for Nephrology and Dialysis Billing

Secondary hyperparathyroidism is nearly universal in patients with ESRD on dialysis. When the kidneys fail, they lose the ability to activate vitamin D and excrete phosphorus—both of which drive PTH overproduction, bone disease, and cardiovascular risk. The three drugs covered under CPB 0022 are first-line injectable tools for managing this condition.

Calcitriol injection is the oldest and most established agent. It's a direct-acting vitamin D receptor agonist typically administered intravenously during dialysis sessions.

Paricalcitol injection (Zemplar) is a selective vitamin D receptor activator that carries a lower risk of hypercalcemia than calcitriol. It became the preferred agent in many dialysis units for higher-risk patients.

Etelcalcetide (Parsabiv) is the newest of the three. As a calcimimetic, it lowers PTH by increasing the sensitivity of the calcium-sensing receptor on parathyroid cells. It is administered intravenously at the end of each hemodialysis session and can be used alone or with a vitamin D analog.

Because these agents are often administered on-site at dialysis facilities, billing for them falls under Part B drug reimbursement rules—and under Aetna commercial or Medicare Advantage plans, coverage criteria can significantly differ from traditional Medicare guidelines. That difference is exactly why a CPB update demands attention.

Affected Codes

The policy data provided for this update does not list specific CPT or HCPCS codes. Billing teams should reference the full policy document directly at https://app.payerpolicy.org/p/aetna/0022 for a complete code listing.

That said, the following HCPCS codes are commonly associated with these drugs in the dialysis and outpatient setting and should be reviewed against the updated policy:

Important: The codes listed below reflect standard industry usage for these agents and are provided for reference only. Do not assume coverage under CPB 0022 without confirming against the actual policy document. No specific codes were listed in the policy data provided with this update.

Confirm each code's coverage status, prior authorization requirements, and any quantity or frequency limits directly in the updated CPB 0022 text before submitting claims under this policy's effective date.

Prior Authorization and Medical Necessity Expectations

Because the full revised policy text was not available in the data provided for this update, specific medical necessity criteria cannot be confirmed here. However, given the drug class and Aetna's historical approach to CPB 0022, billing teams should anticipate that Aetna will likely require documentation of:

Prior authorization requirements for etelcalcetide under Aetna commercial and Medicare Advantage plans have historically been more stringent than for calcitriol, given cost differentials. Confirm whether the February 2026 modification changes any of those thresholds or step-therapy requirements.

What Your Billing Team Should Do